Cargando…

Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics

The SARS-CoV-2 virus needs multiple copies for its multiplication using an enzyme RNA-dependent RNA polymerase (RdRp). Remdesivir inhibits viral RdRp, controls the multiplication of the virus, and protects patients. However, treatment of COVID-19 with remdesivir involves adverse effects. Many ongoin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatterjee, Bhaswati, Thakur, Suman S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134007/ https://www.ncbi.nlm.nih.gov/pubmed/35634324 http://dx.doi.org/10.3389/fimmu.2022.830990

Ejemplares similares

SARS-CoV-2 Infection Triggers Phosphorylation: Potential Target for Anti-COVID-19 Therapeutics
por: Chatterjee, Bhaswati, et al.
Publicado: (2022)

ACE2 as a potential therapeutic target for pandemic COVID-19
por: Chatterjee, Bhaswati, et al.
Publicado: (2020)

Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment
por: Martinez, Miguel Angel
Publicado: (2021)

Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities
por: Wehbe, Zena, et al.
Publicado: (2021)

Editorial: Proteomics and Its Applications in Cancer
por: Thakur, Suman S., et al.
Publicado: (2021)

Repurposing Immunomodulatory Drugs to Combat Tuberculosis
por: Fatima, Samreen, et al.
Publicado: (2021)

Indicator Regularized Non-Negative Matrix Factorization Method-Based Drug Repurposing for COVID-19
por: Tang, Xianfang, et al.
Publicado: (2021)

Differential Cytokine Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir
por: Chan, Yi-Hao, et al.
Publicado: (2021)

Investigation of post-translational modifications in type 2 diabetes
por: Chatterjee, Bhaswati, et al.
Publicado: (2018)

Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing?
por: Khalil, Athar, et al.
Publicado: (2020)

Drug repurposing approach to fight COVID-19
por: Singh, Thakur Uttam, et al.
Publicado: (2020)

Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment
por: Kelleni, Mina T.
Publicado: (2021)

Potential treatments of COVID-19: Drug repurposing and therapeutic interventions
por: Raghav, Pawan Kumar, et al.
Publicado: (2023)

Editorial: Repurposed Drugs as Immune-Modulators to Combat Infectious Diseases
por: Mishra, Bibhuti B., et al.
Publicado: (2022)

Berberine a traditional Chinese drug repurposing: Its actions in inflammation-associated ulcerative colitis and cancer therapy
por: Zhu, Cuipeng, et al.
Publicado: (2022)

Remdesivir as a possible therapeutic option for the COVID-19
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2020)

Repurposed drugs and nutraceuticals targeting envelope protein: A possible therapeutic strategy against COVID-19
por: Das, Gourab, et al.
Publicado: (2021)

Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking
por: Mohapatra, Sovesh, et al.
Publicado: (2020)

Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2
por: Eweas, Ahmad F., et al.
Publicado: (2021)

Drug Repurposing for Atopic Dermatitis by Integration of Gene Networking and Genomic Information
por: Adikusuma, Wirawan, et al.
Publicado: (2021)

COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts
por: Khan, Z., et al.
Publicado: (2021)

In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
por: Shah, Bhumi, et al.
Publicado: (2020)

Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations
por: Wang, Rui-Sheng, et al.
Publicado: (2023)

Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system
por: Punekar, Madhura, et al.
Publicado: (2022)

Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020)

Remdesivir for COVID-19
Publicado: (2020)

Remdesivir and COVID-19
por: Glaus, Matthew J, et al.
Publicado: (2020)

Remdesivir and COVID-19
por: Wang, Lei-Yun, et al.
Publicado: (2020)

Remdesivir and COVID-19
por: Dennis, Alicia
Publicado: (2020)

Remdesivir and COVID-19
por: Edwards, Jessie K, et al.
Publicado: (2020)

Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Translational Control of COVID-19 and Its Therapeutic Implication
por: Zhang, Dejiu, et al.
Publicado: (2022)

Drug repurposing for the treatment of COVID-19
por: Kato, Yuri, et al.
Publicado: (2022)

Perspective: repurposed drugs for COVID-19
por: Na-Bangchang, Kesara, et al.
Publicado: (2022)

Drug repurposing strategies for COVID-19
por: Senanayake, Suranga L
Publicado: (2020)

Repurposing drugs for treatment of COVID-19
por: Venkatesan, Priya
Publicado: (2021)

Repurposing metabolic drugs for COVID-19
por: Bordon, Yvonne
Publicado: (2023)

Drug repurposing using computational methods to identify therapeutic options for COVID-19
por: Mahdian, Soodeh, et al.
Publicado: (2020)

Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures
por: Pizzorno, Andrés, et al.
Publicado: (2019)

Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia
por: Petrakis, Vasilis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ngl3sagr71brr4mnsick53c5uh